Find a Doctor

Dr. Fernando Custodio Fervenza

Mayo Clinic
Nephrology, Internal Medicine
Male
Practicing approx. 39 years
Approx. age 63

Bio


Fernando Fervenza is a Nephrologist and an Internal Medicine specialist in Rochester, Minnesota. Dr. Fervenza is a global expert in C3 Glomerulopathy. He has been an author on 242 peer reviewed articles and participated in 783 clinical trials in the past 15 years. In particular, he has been an author on 27 peer reviewed articles and participated in 1 clinical trial regarding C3 Glomerulopathy. Dr. Fervenza's top three areas of expertise are Membranous Nephropathy, Glomerulonephritis, Focal Segmental Glomerulosclerosis, and Vasculitis. He is licensed to treat patients in MN.

Contact

Rochester, MN 55905, US

Latest Advances


  • Condition: Membranous Nephropathy
  • Journal: The New England journal of medicine
  • Treatment Used: Rituximab or Cyclosporine
  • Number of Patients: 130
  • Published —
The study researched the effectiveness of rituximab versus cyclosporine (both are chemotherapies) in the treatment of membranous nephropathy.
  • Condition: Idiopathic Nephrotic Syndrome
  • Journal: American journal of nephrology
  • Treatment Used: Oral Pulse Dexamethasone
  • Number of Patients: 13
  • Published —
This study tested the safety and efficacy of using oral pulse dexamethasone to treat patients with idiopathic nephrotic syndrome.
  • Condition: C3 glomerulopathy associated with monoclonal Ig
  • Journal: Kidney international
  • Treatment Used: MIg-targeted treatment
  • Number of Patients: 26
  • Published —
The study researched C3 glomerulopathy associated with monoclonal Ig.

Clinical Trials


Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 124
  • Start Date: December 18, 2019
Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI)
Clinical Trial
  • Status: Completed
  • Phase: Phase 3
  • Intervention Type: Drug
  • Participants: 20
  • Start Date: March 2015
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Clinical Trial
  • Status: Completed
  • Phase: Phase 2/Phase 3
  • Intervention Type: Drug
  • Participants: 130
  • Start Date: November 2011
A Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN)
Clinical Trial
  • Status: Recruiting
  • Intervention Type: Procedure
  • Participants: 1200
  • Start Date: April 2010
Nephrotic Syndrome Study Network Under the Rare Diseases Clinical Research Network
Clinical Trial
  • Status: Completed
  • Phase: Phase 4
  • Intervention Type: Drug, Dietary Supplement
  • Participants: 34
  • Start Date: February 2009
A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy
Clinical Trial
  • Status: Completed
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 20
  • Start Date: January 2009
A Dose-Finding Pilot Study of ACTH on the Serum Lipoprotein Profile and Proteinuria in Patients With Idiopathic Membranous Nephropathy (MN)
Clinical Trial
  • Status: Terminated
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 4
  • Start Date: June 2007
A Pilot Study on the Use of Rituximab in the Treatment of Churg- Strauss Syndrome With Renal Involvement
Clinical Trial
  • Status: Completed
  • Phase: Early Phase 1
  • Intervention Type: Drug
  • Participants: 20
  • Start Date: October 2006
Rituximab in the Treatment of Idiopathic Membranous Nephropathy
Clinical Trial
  • Status: Completed
  • Phase: Phase 2/Phase 3
  • Intervention Type: Drug
  • Participants: 15
  • Start Date: August 2004
The Use of Rituximab in the Treatment of Idiopathic Membranous Nephropathy
Clinical Trial
  • Status: Completed
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 18
  • Start Date: December 2002
A Pilot Study of Mycophenolate Mofetil (MMF) in Patients With p-ANCA Microscopic Polyangiitis and Mild to Moderate Renal Dysfunction.

All Publications
View All


  • Journal: Kidney international reports
  • Published —
Immune-Complex Glomerulonephritis After COVID-19 Infection.

Contact

Rochester, MN 55905, US

Affiliations

  • Mayo Clinic Hospital Rochester

Credentials

  • Licenses
    Internal Medicine in MN
  • Board Certifications
    Nephrology

Insurance

Contact them to find out if they accept your insurance plan.